Cytokinetics (CYTK) Q4 2024 earnings summary

Executive summary

• Achieved major regulatory milestones for aficamten: NDA accepted by FDA (U.S.) with PDUFA date set for September 26, 2025, MAA validated by EMA (Europe), and NDA accepted by NMPA (China) with priority review; commercial readiness activities are peaking in the U.S. and expanding in Europe.

• Secured significant partnerships: Bayer for Japan (EUR 50M upfront, up to EUR 580M in milestones/royalties) and Sanofi for China (up to $150M in milestones/royalties), expanding aficamten's global reach.

• Advanced clinical pipeline: MAPLE-HCM top-line results expected Q2 2025; ongoing pivotal trials for label expansion in non-obstructive and pediatric HCM, and new trials for omecamtiv mecarbil and CK-586.

• Strong commercial launch preparations in the U.S. and Europe, including payer engagement, patient support programs, and sales force buildout.

• Ended 2024 with $1.2B in cash, cash equivalents, and investments.

Financial highlights

• Q4 2024 revenues were $16.9M (vs. $1.7M Q4 2023); full-year 2024 revenues $18.5M (vs. $7.5M in 2023), driven by upfront payments from Bayer and Corxel/Sanofi.

• Q4 2024 R&D expenses: $93.6M (vs. $85M Q4 2023); full-year R&D: $339.4M (vs. $330.1M in 2023).

• Q4 2024 G&A expenses: $62.3M (vs. $44.1M Q4 2023); full-year G&A: $215.3M (vs. $173.6M in 2023).

• Q4 2024 net loss: $150M ($1.26/share) vs. $136.9M ($1.38/share) Q4 2023; full-year net loss: $589.5M ($5.26/share) vs. $526.2M ($5.45/share) in 2023.

• Cash, cash equivalents, and investments declined by $60M in Q4 2024, partially offset by a $52.4M payment from Bayer.

Outlook and guidance

• 2025 GAAP operating expense guidance: $670M–$710M (including $110M–$120M stock-based compensation); excluding stock-based comp: $550M–$600M.

• Topline results from MAPLE-HCM expected in Q2 2025; potential U.S. approval and launch of aficamten in 2H 2025; EMA decision expected in 1H 2026; China approval possible in 2H 2025.

• Focused capital allocation on U.S. aficamten launch, pipeline advancement, and muscle biology platform investment.

• Multiple years of cash runway expected, supported by $1.2B cash and access to $500M from Royalty Pharma.

• Anticipated increase in operating expenses reflects investments in commercial readiness for aficamten's potential launch.